査読つき論文（臨床研究の結果）
- REMAP-CAP Writing Committee for the REMAP-CAP Investigators. Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial. JAMA.
https://jamanetwork.com/journals/jama/fullarticle/2799870 - REMAP-CAP Writing Committee for the REMAP-CAP Investigators. Effect of Antiplatelet Therapy on Survival and Organ Support–Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial. JAMA.
https://jamanetwork.com/journals/jama/fullarticle/2790488 - Writing Committee for the REMAP-CAP Investigators. Effect of Convalescent Plasma on Organ Support–Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial. JAMA. 2021.
https://jamanetwork.com/journals/jama/fullarticle/2784914 - Ratcliff J, Nguyen D, Fish M, Rynne J, Jennings A, Williams S, et al. Virological Characterization of Critically Ill Patients With COVID-19 in the United Kingdom: Interactions of Viral Load, Antibody Status, and B.1.1.7 Infection. The Journal of Infectious Diseases. 2021;224(4):595-605.
https://academic.oup.com/jid/article/224/4/595/6283590 - The REMAP-CAP, ACTIV-4a, and ATTACC Investigators. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. New England Journal of Medicine. 2021.
https://www.nejm.org/doi/full/10.1056/NEJMoa2103417 - The REMAP-CAP, ACTIV-4a, and ATTACC Investigators. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. New England Journal of Medicine. 2021.
https://www.nejm.org/doi/full/10.1056/NEJMoa2105911 - Arabi YM, Gordon AC, Derde LPG, Nichol AD, Murthy S, Beidh FA, et al. Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAPrandomized controlled trial. Intensive Care Med. 2021.
https://link.springer.com/article/10.1007/s00134-021-06448-5 - The REMAP‑CAP Investigators. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N Engl J Med. 2021;384(16):1491–502.
https://www.nejm.org/doi/10.1056/NEJMoa2100433 - The REMAP‑CAP Investigators. Effect of Hydrocortisone on Mortality and Organ Support in Patients with Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. JAMA. 2020;324(13):1317–29.
https://jamanetwork.com/journals/jama/fullarticle/2770278.
プレプリント（臨床研究の結果）
プレプリントは査読完了前の論文で、迅速に研究結果を公開するのに役立ちます。現在、査読付き論文として公開されていないプレプリントはありません。
メタアナリシスへの引用
メタアナリシスは、公開されている全ての論文の中から一定の基準に基づいて質の高いものを選び出し、それらの結果を総合して、最善の結論を得る解析手法です。REMAP-CAPは多数のメタアナリシスで引用されています。ここでは、REMAP-CAPを引用しているメタアナリシスの内、特に重要なものを厳選して掲載しています。
- Ma S, Xu C, Liu S, Sun X, Li R, Mao M, et al. Efficacy and safety of systematic corticosteroids among severe COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials. Signal Transduction and Targeted Therapy. 2021;6(1):83.
https://www.nature.com/articles/s41392-021-00521-7#citeas - Axfors C, Schmitt AM, Janiaud P, Van’t Hooft J, Abd-Elsalam S, Abdo EF, et al. Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. Nat Commun. 2021;12(1):2349; https://www.nature.com/articles/s41467-021-22446-z
- The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association between Administration of Systemic Corticosteroids and Mortality among Critically Ill Patients with COVID-19: A Meta-analysis. JAMA. 2020;324(13):1330–41.
https://jamanetwork.com/journals/jama/fullarticle/2770279
査読つき論文（研究システム等）
- The UPMC REMAP-COVID Group on behalf of the REMAP-CAP Investigators. Implementation of the Randomized Embedded Multifactorial Adaptive Platform for COVID-19 (REMAP-COVID) trial in a US health system-lessons learned and recommendations. Trials. 2021;22(1):100.
https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-020-04997-6 - Madani Kia T, Marshall JC, Murthy S. Stakeholder perspectives on adaptive clinical trials: A scoping review. Trials. 2020;21(1):1–10. https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-020-04466-0
- Kamata K, Jindai K, Ichihara N, Saito H, Kato H, Kunishima H, et al. Why participation in an international clinical trial platform matters during a pandemic? Launching REMAP-CAP in Japan. J Intensive Care. 2021;9(1):34. https://jintensivecare.biomedcentral.com/articles/10.1186/s40560-021-00547-7
- Aryal D, Beane A, Dondorp AM, Green C, Haniffa R, Hashmi M, et al. Operationalisation of the Randomized Embedded Multifactorial Adaptive Platform for COVID-19 trials in a low and lower-middle income critical care learning health system. Wellcome Open Res. 2021;6:1–14.
https://wellcomeopenresearch.org/articles/6-14 - Angus DC, Berry S, Lewis RJ, Al-Beidh F, Arabi Y, van Bentum-Puijk W, et al. The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-Acquired Pneumonia) Study. Rationale and design. Ann Am Thorac Soc. 2020;17(7):879–91.
https://www.atsjournals.org/doi/10.1513/AnnalsATS.202003-192SD. - Angus DC, Gordon AC, Bauchner H. Emerging Lessons From COVID-19 for the US Clinical Research Enterprise. JAMA. 2021;325(12):1159–61.
https://jamanetwork.com/journals/jama/fullarticle/2777058
査読付き論文（その他）
- 木庭 茂, 中薗 健一, 斎藤 浩輝, 一原 直昭, 國島 広之, 藤谷 茂樹：国際アダプティブ・プラットフォーム試験REMAP-CAPのプロトコルおよび参加の実際：市中肺炎における抗菌薬およびマクロライド系薬投与期間ドメイン. The Japanese Journal of Antibiotics 2024: 77 (1) 100-106. https://www.jstage.jst.go.jp/article/antibiotics/77/1/77_100/_article/-char/ja/
その他
- 藤井智子, 千田実, 一原直昭. 国際共同研究：その実務と醍醐味. INTENSIVIST(インテンシヴィスト). 2022(3):551-9.
https://www.medsi.co.jp/products/detail/3859 - 神代和明, 一原直昭, 齋藤浩輝, 鎌田一宏, 藤谷茂樹.パンデミック対応型国際臨床研究プラットフォーム：REMAP-CAP.週刊医学界新聞. 2021;第3412号:4-5
https://www.igaku-shoin.co.jp/paper/archive/y2021/3412_03 - Inada M, Ichihara N and Saito H. Global landscape of randomized controlled trials responding to the COVID-19 pandemic: a literature review protocol [version 1; peer review: awaiting peer review]. F1000Research 2023, 12:133 https://doi.org/10.12688/f1000research.129241.1
